Skip to main content
Safe CJC-1295

Immune recognition, hormone effects and the grounds for reassurance.

CJC-1295 references

The hormone experiments, immune concern and other safety questions lead to different kinds of source. The distinctions matter as much as the titles.

Return to the immune questionRead about this site

Reading list

The FDA briefing materials address a regulatory safety concern. Teichman’s healthy-adult studies and Ionescu and Frohman’s pulsatility study supply the principal human hormone measurements. Renehan’s review concerns IGF-1 and cancer associations in population studies.

Jette’s albumin-conjugate experiments involved rats and a cell-free assay; Alba’s growth experiment involved GHRH-deficient mice. The older nitrogen-balance entry concerns ipamorelin and growth hormone in steroid-treated rats, with no CJC-1295 intervention. The list also includes reference descriptions, reviews, a trial registry and sporting rules. I trust each source within the limits of its design.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Growth hormone and growth hormone secretagogue effects on nitrogen balance and substrate metabolism. Growth Horm IGF Res. 2009. ↗
  7. ConjuChem Inc. A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov; 2006. Identifier NCT00267527. ↗
  8. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. ↗
  9. Growth hormone increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab. 2002. ↗
  10. Stanley TL, Grinspoon SK. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. (Tesamorelin, GHRH-analog comparator literature.) 2014. ↗
  11. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  12. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  13. (2026 peptide therapy safety review). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗
  14. (GHRH analog pulsatility/insulin study). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
  15. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting - briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. ↗
  16. Reference summary. Modified GRF (1-29) - chemical and pharmacological description. Encyclopedic reference. 2024. ↗
  17. World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA International Standard. 2025. ↗